Contrave came to market in 2014 as the first oral combination weight loss drug approved by the FDA in nearly a decade. It pairs two old generics, naltrexone and bupropion, into one extended-release tablet aimed at curbing both food cravings and reward-driven eating.<\/p>\n
GLP-1 receptor agonists like semaglutide and tirzepatide arrived later but produce roughly two to three times the weight loss Contrave does. They’ve shifted what patients expect from a weight loss prescription. If you’re comparing the two now, the question is whether Contrave’s lower cost, oral dosing, and behavioral edge are enough to compete with the bigger numbers GLP-1s post.<\/p>\n
The honest answer: for most patients who can access GLP-1s, the weight loss math favors injection. But Contrave still has a real role, especially for patients with binge-eating patterns, smoking concerns, or contraindications to GLP-1s.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Contrave combines naltrexone (an opioid receptor antagonist used in addiction medicine) and bupropion (a dopamine and norepinephrine reuptake inhibitor used as an antidepressant and smoking cessation aid).<\/strong> Bupropion stimulates pro-opiomelanocortin (POMC) neurons in the hypothalamus, which produce satiety signals. Naltrexone blocks the negative feedback loop that normally limits bupropion’s effect on those neurons.<\/p>\n Quick Answer: Contrave produces 5% to 9% mean weight loss at 56 weeks (COR-I, COR-II, COR-BMOD trials)<\/p>\n The combined action targets both homeostatic hunger (the physiological drive to eat) and hedonic eating (food reward and cravings). The drug is taken as two tablets twice daily, escalated over four weeks to minimize side effects.<\/p>\n GLP-1 receptor agonists work entirely differently. They mimic an endogenous gut hormone, slow gastric emptying, amplify satiety in the brainstem and hypothalamus, and reduce food reward signaling. The two drug classes work on overlapping but distinct circuits.<\/p>\n GLP-1s win clearly on average.<\/strong> The Contrave key trials (COR-I, COR-II, COR-BMOD, COR-Diabetes) showed mean placebo-subtracted weight loss of 4.1% to 5.2% at 56 weeks among completers. Absolute weight loss in the active arms was 5% to 9% depending on the trial and adherence.<\/p>\n Semaglutide 2.4 mg in STEP 1 produced 14.9% mean weight loss at 68 weeks. Tirzepatide 15 mg in SURMOUNT-1 hit 20.9% at 72 weeks. Even semaglutide’s lower diabetes doses outperform Contrave’s full dose.<\/p>\n For patients who need to lose 10 to 20 pounds, Contrave can be enough. For patients with substantial obesity needing 30+ pounds of loss, GLP-1s typically reach that target where Contrave doesn’t.<\/p>\n Contrave’s most common side effects are nausea, constipation, headache, vomiting, dizziness, insomnia, dry mouth, and diarrhea.<\/strong> Around 20% to 25% of patients in trials discontinued due to adverse events. Contrave carries a boxed warning for suicidal thoughts and behaviors in young adults (a class effect of bupropion) and is contraindicated in patients with seizure disorders, uncontrolled hypertension, anorexia or bulimia, chronic opioid use, or pregnancy.<\/p>\n GLP-1 side effects are mostly gastrointestinal: nausea, vomiting, diarrhea, constipation, often during the dose-escalation phase. Around 4% to 7% of patients in STEP 1 discontinued for adverse events. GLP-1s have a boxed warning for medullary thyroid C-cell tumors based on rodent data, with no clear human signal in 15+ years of clinical use.<\/p>\n For patients with depression, insomnia, or a seizure history, Contrave is the harder fit. For patients with severe baseline GI dysfunction, GLP-1s can be harder.<\/p>\n This is where Contrave has a unique edge.<\/strong> Bupropion is FDA-approved for smoking cessation as Zyban. Naltrexone is used in alcohol use disorder and opioid use disorder treatment. Patients with co-occurring substance use issues, food addiction patterns, or active smoking goals may get dual benefit from Contrave that GLP-1s don’t provide.<\/p>\n That said, emerging data on GLP-1s and addiction is interesting. Observational studies and a few small trials suggest semaglutide may reduce alcohol craving, nicotine craving, and possibly opioid-seeking behavior. The mechanism likely involves GLP-1’s effect on reward circuitry. Definitive trials are ongoing.<\/p>\n For patients actively trying to quit smoking, Contrave (or just bupropion as Zyban) has the deeper evidence base.<\/p>\n Contrave’s manufacturer offers direct cash pricing of around $99\/month through their savings program.<\/strong> Without that program, retail can hit $700+\/month, though insurance often covers it. Generic naltrexone and generic bupropion can be prescribed separately for under $30\/month combined, though dosing has to be managed by the prescriber.<\/p>\n GLP-1 brand prices are higher. Brand Wegovy\u00ae is around $1,349\/month at list, Zepbound\u00ae around $1,086\/month. Compounded semaglutide and tirzepatide through telehealth like TrimRx typically run $200 to $500\/month.<\/p>\n So Contrave is cheaper at brand pricing, comparable at compounded GLP-1 pricing, and notably cheaper if a clinician prescribes the generic components separately.<\/p>\n Key Takeaway: Tirzepatide reaches 20.9% at 72 weeks (SURMOUNT-1, Jastreboff et al. 2022 NEJM)<\/p>\n Both have a slow onset.<\/strong> Contrave is titrated up over four weeks to minimize side effects, with appetite suppression building gradually. Most patients notice meaningful appetite changes by weeks 3 to 6. Peak effect builds over 12 to 24 weeks.<\/p>\n GLP-1s also titrate. Semaglutide starts at 0.25 mg weekly and steps up over 16 weeks to 2.4 mg. Many patients feel appetite suppression in the first weeks at low doses. Tirzepatide follows a similar 20-week titration pattern. Peak effect typically appears between months 4 and 12.<\/p>\n Neither drug produces dramatic week-one results, and both reward patience.<\/p>\n Yes, off-label, and some obesity medicine clinicians do exactly this for patients who plateau or have specific symptom patterns.<\/strong> The two drugs work on overlapping but distinct pathways, so combination therapy is mechanistically sensible. Published data on the combination is limited to small observational reports.<\/p>\n The combination has to be screened carefully for bupropion’s seizure risk, contraindications to either drug, and additive side effect burden. Most patients won’t need both. For those who do, a clinician familiar with obesity pharmacotherapy should oversee the regimen.<\/p>\n Contrave fits patients with binge-eating or hedonic eating patterns, those who also want help quitting smoking, patients who prefer oral dosing over injection, those with limited budget who can use the $99 program, and patients with contraindications to GLP-1s (severe gastroparesis, history of medullary thyroid carcinoma, MEN2 syndrome).<\/strong><\/p>\n It doesn’t fit patients with seizure disorders, uncontrolled hypertension, eating disorders involving restriction, chronic opioid users, or those needing substantial weight loss beyond Contrave’s typical 5% to 9% range.<\/p>\n GLP-1s fit patients with substantial obesity who need 15%+ weight loss, those with comorbidities like type 2 diabetes, cardiovascular disease, sleep apnea, or chronic kidney disease, patients who tolerated lower-dose GLP-1s previously, and those willing to commit to weekly injection and long-term therapy.<\/strong><\/p>\n At TrimRx, the free assessment quiz screens eligibility for compounded semaglutide and tirzepatide and routes appropriate patients to a personalized treatment plan.<\/p>\n Bottom line: Contrave runs around $99\/month direct; compounded GLP-1 runs $200 to $500\/month<\/p>\n No. Neither component is scheduled. Naltrexone is not controlled. Bupropion is not controlled. This makes Contrave easier to prescribe and refill than scheduled options like phentermine.<\/p>\n Alcohol is best avoided or minimized on Contrave. Bupropion lowers seizure threshold, and alcohol can compound that risk. Naltrexone also blocks the rewarding effects of alcohol, so drinking feels different and unpleasant for many patients on the drug.<\/p>\n Yes, like most chronic weight loss medications, stopping Contrave typically leads to some weight regain. The Contrave trials weren’t designed for long-term off-drug follow-up, but obesity in general behaves like a chronic disease requiring ongoing treatment.<\/p>\n Possibly. Bupropion is an effective antidepressant on its own. Some patients on Contrave report mood improvement. That said, Contrave isn’t FDA-approved as an antidepressant and isn’t a substitute for treating diagnosed depression with appropriate dosing and monitoring.<\/p>\n Yes, this is a common combination. There’s no direct pharmacological interaction between GLP-1s and bupropion. Some clinicians actively prefer this combination for patients with both obesity and depression or smoking goals.<\/p>\n It depends on the patient. Contrave has a worse profile in seizure-prone or hypertensive patients. GLP-1s have a worse GI profile and a theoretical thyroid concern. For most patients, both are manageable. The SELECT trial showed cardioprotection with semaglutide that Contrave doesn’t have.<\/p>\n Most patients see noticeable appetite reduction within 3 to 6 weeks of starting Contrave at full dose. Meaningful weight loss usually shows up by month 3, with continued progress through month 6 to 12 in responders.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Contrave came to market in 2014 as the first oral combination weight loss drug approved by the FDA in nearly a decade.<\/p>\n","protected":false},"author":11,"featured_media":92992,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"GLP-1 vs Contrave: Comparing Weight Loss Prescriptions","_yoast_wpseo_metadesc":"Contrave came to market in 2014 as the first oral combination weight loss drug approved by the FDA in nearly a decade.","_yoast_wpseo_focuskw":"glp1 contrave","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[12],"tags":[21,29,56],"class_list":["post-89929","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-weight-loss","tag-comparisons","tag-glp-1","tag-weight-loss"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89929","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=89929"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89929\/revisions"}],"predecessor-version":[{"id":91516,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/89929\/revisions\/91516"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/92992"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=89929"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=89929"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=89929"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Which Produces More Weight Loss?<\/h2>\n
What’s the Side Effect Profile?<\/h2>\n
What About Smoking and Addiction?<\/h2>\n
What Does Each Cost?<\/h2>\n
Which Works Faster?<\/h2>\n
Can You Combine Contrave with a GLP-1?<\/h2>\n
Who’s a Good Candidate for Contrave?<\/h2>\n
Who’s a Good Candidate for GLP-1?<\/h2>\n
FAQ<\/h2>\n
Is Contrave a Controlled Substance?<\/h3>\n
Can I Drink Alcohol on Contrave?<\/h3>\n
Does Contrave Cause Weight Regain After Stopping?<\/h3>\n
Will Contrave Help with Depression?<\/h3>\n
Can I Take a GLP-1 If I’m Already on Bupropion?<\/h3>\n
Is Contrave Safer Than GLP-1s?<\/h3>\n
How Long Does Contrave Take to Work?<\/h3>\n